Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2024-06-05 00:00:00 ET · period of report 2024-06-04 · accession 0001415889-24-015533 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-05 | 2024-06-04 | QNCX | Hannah Brendan | Chief BUSINESS Off. AND COO | M - OptEx | $0.55 | +56.1K | 257.6K | +28% | +$30.8K |
| D | 2024-06-05 | 2024-06-04 | QNCX | Hannah Brendan | Chief BUSINESS Off. AND COO | M - OptEx | $0.00 | -56.1K | 47.4K | -54% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-04 | M | A | 56,061 | $0.55 | 257,616 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-06-04 | M | D | 56,061 | $0.00 | 47,439 | D | $0.55 · — to 2032-03-27 | 56,061 Common Stock | (F1) The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. |